PortfoliosLab logoPortfoliosLab logo
IRWD vs. IMVT
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

IRWD vs. IMVT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ironwood Pharmaceuticals, Inc. (IRWD) and Immunovant, Inc. (IMVT). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

IRWD vs. IMVT - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
IRWD
Ironwood Pharmaceuticals, Inc.
4.15%-23.93%-61.28%-7.67%6.26%2.37%-14.43%-1.48%
IMVT
Immunovant, Inc.
-2.28%2.62%-41.21%137.35%108.33%-81.55%191.05%-0.69%

Fundamentals

EPS

IRWD:

$0.21

IMVT:

-$2.65

Total Revenue (TTM)

IRWD:

$296.15M

IMVT:

$0.00

Gross Profit (TTM)

IRWD:

$221.01M

IMVT:

-$105.00K

EBITDA (TTM)

IRWD:

$121.85M

IMVT:

-$372.49M

Returns By Period

In the year-to-date period, IRWD achieves a 4.15% return, which is significantly higher than IMVT's -2.28% return.


IRWD

1D
8.67%
1M
2.63%
YTD
4.15%
6M
167.94%
1Y
138.78%
3Y*
-30.64%
5Y*
-20.25%
10Y*
-10.96%

IMVT

1D
5.48%
1M
-10.42%
YTD
-2.28%
6M
54.09%
1Y
45.35%
3Y*
17.00%
5Y*
8.07%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IRWD vs. IMVT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IRWD
IRWD Risk / Return Rank: 7979
Overall Rank
IRWD Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
IRWD Sortino Ratio Rank: 8383
Sortino Ratio Rank
IRWD Omega Ratio Rank: 7777
Omega Ratio Rank
IRWD Calmar Ratio Rank: 8181
Calmar Ratio Rank
IRWD Martin Ratio Rank: 7575
Martin Ratio Rank

IMVT
IMVT Risk / Return Rank: 6969
Overall Rank
IMVT Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
IMVT Sortino Ratio Rank: 6969
Sortino Ratio Rank
IMVT Omega Ratio Rank: 6363
Omega Ratio Rank
IMVT Calmar Ratio Rank: 7272
Calmar Ratio Rank
IMVT Martin Ratio Rank: 7070
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IRWD vs. IMVT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ironwood Pharmaceuticals, Inc. (IRWD) and Immunovant, Inc. (IMVT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


IRWDIMVTDifference

Sharpe ratio

Return per unit of total volatility

1.19

0.82

+0.38

Sortino ratio

Return per unit of downside risk

2.27

1.55

+0.72

Omega ratio

Gain probability vs. loss probability

1.27

1.17

+0.09

Calmar ratio

Return relative to maximum drawdown

2.42

1.59

+0.83

Martin ratio

Return relative to average drawdown

4.56

3.36

+1.20

IRWD vs. IMVT - Sharpe Ratio Comparison

The current IRWD Sharpe Ratio is 1.19, which is higher than the IMVT Sharpe Ratio of 0.82. The chart below compares the historical Sharpe Ratios of IRWD and IMVT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


IRWDIMVTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.19

0.82

+0.38

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.28

0.11

-0.39

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.18

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.13

0.09

-0.22

Correlation

The correlation between IRWD and IMVT is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

IRWD vs. IMVT - Dividend Comparison

Neither IRWD nor IMVT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IRWD vs. IMVT - Drawdown Comparison

The maximum IRWD drawdown since its inception was -97.31%, roughly equal to the maximum IMVT drawdown of -93.59%. Use the drawdown chart below to compare losses from any high point for IRWD and IMVT.


Loading graphics...

Drawdown Indicators


IRWDIMVTDifference

Max Drawdown

Largest peak-to-trough decline

-97.31%

-93.59%

-3.72%

Max Drawdown (1Y)

Largest decline over 1 year

-60.67%

-20.98%

-39.69%

Max Drawdown (5Y)

Largest decline over 5 years

-96.33%

-79.94%

-16.39%

Max Drawdown (10Y)

Largest decline over 10 years

-97.31%

Current Drawdown

Current decline from peak

-83.34%

-52.87%

-30.47%

Average Drawdown

Average peak-to-trough decline

-38.79%

-54.24%

+15.45%

Ulcer Index

Depth and duration of drawdowns from previous peaks

32.67%

10.49%

+22.18%

Volatility

IRWD vs. IMVT - Volatility Comparison

Ironwood Pharmaceuticals, Inc. (IRWD) has a higher volatility of 21.52% compared to Immunovant, Inc. (IMVT) at 14.73%. This indicates that IRWD's price experiences larger fluctuations and is considered to be riskier than IMVT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


IRWDIMVTDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.52%

14.73%

+6.79%

Volatility (6M)

Calculated over the trailing 6-month period

76.33%

37.06%

+39.27%

Volatility (1Y)

Calculated over the trailing 1-year period

117.03%

56.17%

+60.86%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

71.72%

75.18%

-3.46%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.32%

77.70%

-17.38%

Financials

IRWD vs. IMVT - Financials Comparison

This section allows you to compare key financial metrics between Ironwood Pharmaceuticals, Inc. and Immunovant, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
47.71M
0
(IRWD) Total Revenue
(IMVT) Total Revenue
Values in USD except per share items